AI is transforming healthcare, paving the way for breakthroughs in precision medicine and unlocking extraordinary value. On the Disruption Interruption podcast, Elucidata CEO Abhishek Jha discusses how a data-centric approach addresses life sciences’ unique challenges. Discover the critical role of clean, structured data in driving AI-powered innovation and advancing the future of healthcare.
TAMPA BAY, Fla., Jan. 14, 2025 /PRNewswire-PRWeb/ — AI has the potential to revolutionize healthcare, with McKinsey estimating it could unlock up to $1 trillion in value across the industry. (1) This week on the Disruption Interruption podcast, host Karla Jo Helms (KJ) explores this transformative frontier with Abhishek Jha, Co-Founder and CEO of Elucidata—a biotech innovator at the intersection of AI and computational biology, driving advancements in precision medicine.
“The AI paradigm that worked for tech will not carry over to life sciences… it’s time for data-centric AI” — Abhishek Jha, Co-Founder and CEO of Elucidata
Jha sheds light on the immense opportunities AI presents while addressing critical challenges the healthcare sector must overcome to fully harness its potential. “The AI paradigm that worked for tech will not carry over to life sciences… it’s time for data-centric AI,” he asserts, emphasizing the need for a tailored approach to innovation in medicine.
Computational Biology: Simulating Science, Accelerating Discovery
Jha explains that computational biology allows researchers to simulate biological processes in the same way the aviation industry uses models to simulate flight conditions. “You cannot test your plane in every condition; it’s a very expensive and slow process,” he notes. Similarly, researchers can test and refine models before applying them in real-world experiments, making the process more efficient.
By iteratively refining these models based on experimental feedback, scientists can better understand intricate biological mechanisms. “If the model is good, you can make some predictions, go back, and test it. If not, you improve your model,” Jha illustrates.
The Trillion-Dollar Problem: Bridging the Gap Between Tech and Life Sciences
One of the most critical challenges between tech companies and life sciences is the sheer volume of data available. “They think they have a trillion-dollar problem, but they have hundreds of ten-million-dollar problems,” states Jha. As he explains, the entire paradigm must shift to adapt to a world where many valuable problems exist, rather than focusing on a singularly valuable one.
Tech giants like Google benefit from access to billions of users generating data daily, providing them with an immense pool of information to fuel AI models. In contrast, life sciences data—while equally critical—remains far scarcer and harder to obtain. For instance, even large clinical trials for widespread conditions like breast cancer typically involve only a few thousand patients, a scale that pales in comparison to the vast data sources available to tech companies.
“There’s a significant disparity,” Jha points out. “How much data about my purchasing habits is available versus my health data? We don’t have access to that, nor is it consolidated in one single place.”
Clean Data Over Big Data: The Key to AI Success
Data cleaning and preparation are often underestimated in AI workflows, particularly in life sciences. Abhishek Jha compares this to “technical debt,” where rushing to amass data without proper structuring leads to long-term challenges. For instance, inconsistent terms like “hepatitic carcinoma” and “liver cancer” across datasets create inefficiencies, forcing researchers to spend months standardizing data before analysis.
“Clean data is always more valuable than more data,” Jha emphasizes. “Investing in a thoughtful data strategy is crucial for AI success.” Without standardized terminology and organized datasets, life sciences risk delaying breakthroughs and limiting the potential of AI-driven innovation.
Links
Disrupting Drug Development Delays: How Abhishek Jha’s Elucidata Is Powering Faster Medical Advances with AI
https://omny.fm/shows/disruption-interruption/disrupting-drug-development-delays-how-abhishek-jh
LinkedIn: https://www.linkedin.com/in/abhishek-jha-ba20a821/
Company Website: https://www.elucidata.io/
Disruption Interruption is the podcast where you will hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.
Disruption Interruption can be listened to in Apple’s App Store and Spotify.
About Disruption Interruption™
Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping, logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at http://www.disruption-interruption.com.
About Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a trailblazing biotech company recognized as one of Fast Company’s Most Innovative Biotech Companies of 2024. Under his leadership, Elucidata has transformed biological discovery by leveraging data-centric approaches and cutting-edge AI and ML innovations.
Elucidata’s flagship platform, Polly, accelerates research by harmonizing multi-modal biomedical data—such as Omics, Assay, Real-World, Clinical, EHR, and CRO data—into a Unified Data Model. Polly’s LLM-powered curation enables 10x faster data preparation with 99.99% accuracy, drastically reducing the time to actionable insights and advancing precision medicine.
Before founding Elucidata in 2015, Abhishek spent nearly six years as a Senior Scientist at Agios Pharmaceuticals, contributing to the development of four first-in-class drugs. His experience includes designing algorithms to integrate high-throughput metabolic data with transcriptional data and deploying visualization tools for clinical applications.
Abhishek holds a Postdoctoral Fellowship from MIT, where he developed computational models in immunology, and his career has been defined by a passion for combining technology and science to revolutionize patient outcomes. Beyond his professional pursuits, Abhishek enjoys discussing innovations in biotech and mentoring the next generation of entrepreneurs.
About Karla Jo Helms
Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.
References
1. Bhasker, Shashank, et al. “Tackling Healthcare’s Biggest Burdens with Generative AI.” mckinsey.com, 10 July 2023, http://www.mckinsey.com/industries/healthcare/our-insights/tackling-healthcares-biggest-burdens-with-generative-ai.
Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4629, khelms@jotopr.com, jotopr.com
View original content to download multimedia:https://www.prweb.com/releases/disrupting-computational-biology-elucidatas-ai-revolutionizes-life-sciences-302350601.html
SOURCE Disruption Interruption